Medtech AI platform raises $25M

Odaia, a company developing an artificial intelligence-powered pharmaceutical platform, raised $25 million in series B financing.

Odaia's Maptual platform aims to help life science companies get drugs and vaccines to the market by streamlining the process of connecting them with providers. In 2022, the company reported a 646 percent growth in year-over-year annual recurring revenue, according to a May 1 Odaia news release.

Threshold Ventures led the financing round.

"Even in a challenging funding environment, our valued investors clearly recognized the significant problem we're solving for the pharmaceutical industry," Odaia CEO and co-founder Philip Poulidis said in the release. "With these funds, we'll continue to evolve our product and build out our team to ensure we're able to offer our existing and future life science brands the predictive tools needed for today's market, and tomorrow's."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars